Efavirenz versus nevirapine as a non-nucleoside reverse transcriptase inhibitor in initial combination antiretroviral therapy for HIV infection
Lawrence C. E. Mbuagbaw, James Irlam
Abstract
Lawrence C. E. Mbuagbaw, James Irlam
Abstract
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To determine which NNRTI—EFV or NVP—is more effective in terms of viral load suppression when given in combination with two NRTIs as part of initial ARV combination therapy for HIV infection in adults and children.
OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To determine which NNRTI—EFV or NVP—is more effective in terms of viral load suppression when given in combination with two NRTIs as part of initial ARV combination therapy for HIV infection in adults and children.
Key concepts: Nevirapine, Efavirenz, Medicine, Reverse-transcriptase inhibitor, Nucleoside Reverse Transcriptase Inhibitor, Virology, Human immunodeficiency virus (HIV), Antiretroviral therapy